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antidepressants only, $35,099 for psychotherapy only, $33,032 for both and $34,041 
for those receiving no depression treatment. Adjusted linear mixed model analy-
sis revealed that as compared to no depression treatment, depression treatment 
with antidepressants only, psychotherapy only and by both antidepressants and 
psychotherapy reduced total healthcare expenditures by 17%(p-value< 0.001), 
22%(p-value< 0.001) and 28%(p-value< 0.001) respectively. CONCLUSIONS: 
Depression treatment reduced healthcare expenditures suggesting that among 
individuals with T2DM who develop depression, prioritizing treatment for depres-
sion can result in economic benefits.
PDB94
Evolution of thE MarkEt for oral antiDiaBEtic agEnts in canaDa 
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OBJECTIVES: Type 2 diabetes mellitus (DM) accounts for over 90% of all diagnosed 
diabetes cases. Hyperglycemia is an important risk factor for diabetic compli-
cations, supporting the use of glucose-lowering agents in the treatment of dia-
betes. Among glucose-lowering agents to treat type 2 DM are oral antidiabetic 
(OAD) agents. The objective of this study was to evaluate the Canadian market 
for OAD agents since 2008, soon after dipeptidyl peptidase (DPP)-4 inhibitors 
were introduced. METHODS: Data on retail prescriptions and on drugstore and 
hospital purchases of OAD agents in Canada were obtained from IMS Brogan. 
Number of prescriptions and purchases (in $Can) were collected for 2008, 2012 
and 2014. RESULTS: Total number of prescriptions for OAD agents in Canada 
amounted to 13.6 million, 20.5 million and 23 million in 2008, 2012, and 2014, 
respectively. Contribution of the two OAD agents mainly prescribed, metformin 
and sulfonylureas, decreased during this period while percentage of prescriptions 
for DPP-4 inhibitors over total OAD agents increased from 0.075% to 6.5% and to 
14.5%, respectively, driven by the increase in prescriptions of sitagliptin, sitaglip-
tin/metformin, saxagliptin, and linagliptin. Total drugstore and hospital purchases 
for OAD agents in Canada reached $394.2 million, $418.7 million and $520.9 million 
in 2008, 2012, and 2014, respectively. Percentage of purchases of DPP-4 inhibitors 
over total OAD agents markedly increased during this period, from 0.5% to 34.1% 
and to 64.1%, respectively. CONCLUSIONS: OAD agents represent a market of 
more than half a billion dollars in Canada; this will likely continue to grow due to 
the increasing occurrence of cases of type 2 DM in the general population. Since 
their introduction in 2008, DPP-4 inhibitor use has grown rapidly so that in 2014, 
they captured approximately one-sixth of prescriptions and, at almost two-thirds 
of purchases, were the market leaders among OAD agents.
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OBJECTIVES: Info-Diabetics’ is becoming an imperative approach in E-health to 
stipulate the diabetic patient care and management. In this study we tried to get an 
overview for application of cellular phone text messaging over adolescent diabetic 
patients (ADPs). The major objective of this study was to test whether adding cellular 
application for patient care compared with control cases would reduce Glycated 
Hemoglobin (HbA1c). METHODS: Eleven ADPs (study cases, n= 11) were selected for 
mobile phone coaching through text messaging, to consultants. ADPs of the control 
site (n= 09) were continued with their standard diabetes health care from consult-
ants. Primarily ADPs were enquired for demographic and social characteristics, 
frequency of cellular phone use, general health information and diagnosis of type 
2 diabetes. Further the level of Hb1Ac, in both the groups, was measured in a regular 
interval of 45 days. After 225 days, percentage of mean improvement in Hb1Ac level 
was compared between cellular users and control cases. RESULTS: More than 3% 
improvement in Hb1Ac was observed among the patients having mobile phone and 
they made regular interaction with consultant. The differences were very small but 
a trend of positive improvement was observed among ADPs using cellular phone’s 
text messaging. CONCLUSIONS: Result indicated that info-diabetic approach may 
contribute to minimize complexities in medical care and the cautious use of cel-
lular phone technology in the form of text messaging would be an asset for self 
care management in ADPs.
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BACKGROUND: In a recent commentary (Basu ERPOR2015), we proposed a solution 
to financing cures in the presence of multiple payers by recommending develop-
ment of a tradable new currency, HealthCoin, which would convert the incremental 
consequences produced by certain well-established cures to a common numeraire 
that can be traded with real dollars in the marketplace among private and pub-
lic payers. OBJECTIVES: To develop the theory behind the provision of a tradable 
HealthCoin for a cure for diabetes between a private payer that provides coverage 
for non-elderly adults, and a public payer (e.g. Medicare) covering the elderly popu-
lation. METHODS: We identify the conditions under which the either payer lacks 
incentive to pay for the cure and where a HealthCoin can overcome these incentives 
problems. We illustrate this theory using empirical estimates for cost-savings and 
life-years gain generated by a cure for diabetes. RESULTS: We find that the precise 
condition required for the valuation of a HealthCoin that would incentivize the 
public payer to offer the HealthCoin as a payment to the private payer, which in turn 
would now have the incentive to purchase the cure, is min{INMBMedicare, PCure} ≥ 
two subsequent prescriptions.   Time to discontinuation was analyzed using 
Kaplan-Meier and Cox proportional hazards regression, including demograph-
ics, treatment background, and diabetes-related complications/comorbidities as 
covariates. RESULTS: 66,206 patients (mean age 52.6 years; 50% male; median/
maximum follow-up, 10.1/19.0 months) were identified in the Truven database. 
After one year, the percentage of patients still on treatment was significantly 
higher with canagliflozin 100 mg (n=7,445; 64.0%) and 300 mg (n=4,486; 65.0%) 
versus DPP-4 inhibitors (30.2% [linagliptin] to 50.1% [sitagliptin]) and GLP-1 ago-
nists (24.3% [exenatide] to 43.0% [liraglutide]) (P <0.0001 for all comparisons).  The 
adjusted hazard ratio (HR) for time to discontinuation for canagliflozin 100 mg 
(reference) and 300 mg (HR=0.92 [0.86;0.99]) was significantly lower versus DPP-4 
inhibitors and GLP-1 agonists: sitagliptin (n=29,426; HR=1.28 [1.22;1.34]); saxagliptin 
(n=1,566; HR=2.01 [1.86;2.16]); linagliptin (n=1,432; HR=2.08 [1.92;2.24]); exenatide 
(n=2,376; HR=2.59 [2.41;2.77]); exenatide long-acting (n=5,922; HR=1.46 [1.40;1.52]); 
liraglutide (n=17,690; HR=1.23 [1.20;1.27]).  Being younger, male, and being on 
monotherapy were associated with higher discontinuation risk.  HRs were stable 
across sensitivity analyses using alternative discontinuation definitions.  Analyses 
from Optum were generally consistent with these results. CONCLUSIONS: These 
analyses indicate that patients who received canagliflozin versus DPP-4 inhibi-
tors or GLP-1 agonists remained on their therapy longer, which may reflect better 
effectiveness and/or tolerability.
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OBJECTIVES: Within the US type 2 diabetes mellitus (T2DM) treatment, following 
metformin failure, is thought to be quite variable given a broad treatment arma-
mentarium. We therefore, sought to determine if newer agent classes or patient 
age influenced prescribing patterns. METHODS: De-identified prescriptions from 
the T2DM analytic platform of the Humedica electronic health records database 
were described, 1/1/2010-6/30/2014. RESULTS: Selection criteria were met by 193,592 
T2DM patients, of whom 71,452 (37%) were ≥ 65 years-old (“elderly”). Of first-line pre-
scriptions, metformin was the most common (59%) followed by SUs (13%), basal (9%) 
and other insulins (9%), DDP4s and DDP4 fixed-dose-combinations (5%), GLP1 (2%), 
TZDs (2%); others ≤ 1%. Metformin first-line monotherapy was prescribed to 140,055 
patients. Of these, 112,387 (80%) remained on monotherapy or discontinued without 
receiving subsequent prescriptions, only 20% progressed to a second-line therapy. 
Top second-line prescriptions were for: metformin+SU (30%), SU monotherapy 
(16%), metformin+DPP4 (9%), DPP4 monotherapy (6%), metformin+basal insulin (4%), 
metformin+GLP1 (4%), DPP4 FDC (4%), metformin+other insulin (3%); others < 3%. 
The elderly received first-line prescriptions for: metformin (49%), SU (18%), insulins 
(basal, 10%; other, 11%), DPP4 FDCs (6%), TZDs (3%), other FDCs (1%), and GLP1s 
(1%). Of the 42,852 elderly receiving metformin monotherapy, 81% either continued 
metformin monotherapy or discontinued without receiving subsequent prescrip-
tions, with 19% progressing to second-line. Top second-line prescriptions among 
the elderly were: metformin+SU (29%), SU monotherapy (22%), metformin+DPP4 
(9%), DPP4 monotherapy (8%), metformin+other insulin (4%), metformin+basal 
insulin (4%), insulin (basal, 3%; other 3%), others < 3%. CONCLUSIONS: First-line 
metformin was most commonly prescribed. Interestingly, despite the availability 
of newer agents classes (e.g., DDD4, GLP1s), most common second-line therapy was 
SU add-on to metformin or monotherapy. Contrary to popular beliefs, we observed 
no age-related differences in prescribing patterns. The outcomes and costs of such 
treatment patterns in the elderly relative to hypoglycemia and its sequelae war-
rants further evaluation.
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OBJECTIVES: To examine whether depression treatment is associated with health-
care expenditures among Medicaid beneficiaries with Type 2 Diabetes Mellitus 
(T2DM) and newly-diagnosed depression. METHODS: A retrospective longitudi-
nal repeated measures cohort design was used.Multi-year (2000-2008) three-state 
Medicaid data were used.The cohort included non-elderly, fee-for-service, continu-
ously enrolled Medicaid beneficiaries with T2DM and newly-diagnosed depression 
(N= 5,295).The depression diagnosis date was the “index-date”; baseline and fol-
low-up periods were defined as 12-months prior and subsequent to the index-date.
Depression treatment received in 120 days after index-date was categorized as, 
treatment with antidepressants only,psychotherapy only,both antidepressants and 
psychotherapy and no treatment.Total healthcare expenditures were calculated for 
each follow-up month.Linear mixed effects regressions on log transformed total 
expenditures were used to examine associations between depression treatment 
and monthly healthcare expenditures after adjusting for random intercept and 
fixed effects of time in months, depression treatment , types of co-existing chronic 
physical conditions (hierarchically classified based on their similarity to T2DM 
pathophysiology and/or management into dominant,concordant only,discordant 
only and both concordant and discordant), gender, age, race/ethnicity, other men-
tal health conditions, Medicaid eligibility due to poverty/medical need/waiver 
(yes/no), baseline healthcare utilization and county of residence characteristics 
such as presence of healthcare infrastructure( e.g.community mental health care 
clinic) and social determinants of health (e.g.county median income). RESULTS: 
Overall,57% had depression treatment (antidepressants only:27.3%, psychotherapy 
only:18.1% and both:11.4%). The average yearly expenditures were $30,590 for 
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requiring medical assistance (DC= 6.0, DT= 5.9), HE requiring non-medical assistance 
(DC= 5.9, DT= 5.9), other HE not requiring assistance (DT= 5.7), and treatment goals 
not being met (DC= 5.6). Compared to current users, DT and DC patients were more 
likely to have experienced ≥ 1 HE in the previous year (DC= 41.0%, DT= 43.1% vs. 
current= 8.8%; p< .05), and experienced a greater mean number of events per year 
(DC= 1.59, DT= 1.47 vs. current= 0.24, p< .05). Having ≥ 1 HE requiring medical assis-
tance in the previous year was more common among DC patients than DT or current 
patients (DC= 7.4%, DT= 4.3%, current= 4.8%; p< .05). CONCLUSIONS: Hypoglycemia 
and glycemic control emerged as the most important concerns physicians have 
when deciding to DC or DT SU therapy. DC and DT patients were more likely to have 
experienced HE, and with greater severity, than current SU patients.
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OBJECTIVES: While change in glycated hemoglobin (A1C) is typically used as the 
primary measure of efficacy in clinical trials of diabetes medications, quality of care 
in “real-world” clinical practice is often assessed based on attainment of patient-
specific A1C targets, as recommended in HEDIS 2014 performance benchmarks by 
the National Committee for Quality Assurance. HEDIS measures are used by US 
health plans to measure care and service performance. To assist in the design of 
pragmatic clinical trials for new insulin glargine 300 U/ml (Gla-300), we estimated 
A1C targets for T2DM patients initiating basal insulin in real-world clinical prac-
tice, using a large retrospective database and data from a clinical trial. METHODS: 
Insulin-naïve T2DM patients initiating basal insulin were identified in both the 
Ingenix Impact National Managed Care (IMPACT) database (n= 22,428) and EDITION 
3 (n= 862), a clinical trial of Gla-300. Patients were stratified according to whether 
they were aged < 65y and free of selected comorbidities (A1C target < 7.0%), or aged 
≥ 65y and/or with one or more comorbidities (A1C target < 8.0%), according to HEDIS 
measures. RESULTS: In the IMPACT database, mean age was 52y, and mean baseline 
A1C (SD) was 9.0% (±2.7) in those with available A1C. Patients aged < 65y without 
comorbidities (target < 7.0%) constituted 68.1% of the sample, while 31.9% were 
aged ≥ 65y and/or had comorbidities (target < 8.0%). In the EDITION 3 trial, mean age 
was 58y, and mean baseline A1C (SD) was 8.5% (±1.1). Patients aged < 65y without 
comorbidities (target < 7.0%) constituted 73.0%, and 27.0% were aged ≥ 65y and/or 
had comorbidities (target < 8.0%). CONCLUSIONS: The distribution of T2DM patients 
initiating basal insulin by A1C target, based on HEDIS performance measures, was 
similar in both real-world and clinical trial settings. Findings from trials therefore 
may be useful in the design of pragmatic clinical trials of Gla-300.
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OBJECTIVES: The aim of the study was to measure the effect of diabetes educational 
program on type 2 diabetic patients. METHODS: In total, a convenient sample of 
215 patients were attended a group-based educational intervention session about 
diabetes which is conducted by a researcher. Knowledge evaluation questionnaire 
were evaluated at pre and post test. Anthropometric measurements and lab tests 
were measured at pre and post test. Significance of the results was assessed by 
paired t- test at 95% confidence interval using SPSS version 16. RESULTS: BMI was 
decreased significantly after educational intervention, (from 32.1±5.76 to 31.23±5.8) 
(p = 0.000). Moreover, a significant decrease in glycosylated hemoglobin after edu-
cational intervention were reported, (from 8.57± 1.21 to 7.95±1.42) (p = 0.000).A sig-
nificant increase in knowledge evaluation test scores were shown after educational 
intervention (from 60.6±20.65 increased to 78.1±13.4) (p = 0.000). CONCLUSIONS: 
Diabetes education is a cornerstone in the management and care of diabetes and 
should be an integral part of health planning involving patient’s family, diabetes 
care team, community and decision makers in the education process.key words 
Diabetes, Educational, Program, Intervention.
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OBJECTIVES: It is important to understand diabetes treatment patterns over time. 
This study compared changes in comorbidities, treatment patterns, and costs 
among newly-diagnosed T2D patients in 2007 and 2012. METHODS: Separate 
cross-sectional analyses of medical treatments, diagnoses, and pharmacy claims 
in the Truven Health MarketScan® Database were conducted for 2007 and 2012. 
Criteria for newly-diagnosed T2D were enrolment 6 months prior to index, ≥ 2 
diagnoses for T2D (ICD-9 codes), ≥ 18 years old, and continuous enrolment in 
a plan with prescription benefits for ≥ 1 year. RESULTS: Comparing 2007 with 
2012, T2D incidence rate decreased from 1.1% to 0.65% of all enrolled patients. 
Hyperlipidemia (46% and 57%) and hypertension (55 % and 62%) were the 2 most 
prevalent comorbidities. 46% and 57% of patients in 2007 and 2012 used only oral 
anti-diabetic drugs (OADs). Single OAD use increased from 68% to 77% of these 
patients. Metformin (Met) was the most prevalent OAD monotherapy, amounting 
to 75% and 90% of single OAD prescriptions. SU monotherapy fell from 14% to 6%. 
Met+SU, the most widely used dual OAD combination, grew from 48% to 57% of 
dual users. Met+TZD use fell from 30% to 0%, replaced by Met+DPP-IV (34%). An 
insulin-only regimen was used by 1.4% and 1.6% of patients for 2007 and 2012, 
and insulin+OADs were used by 2.5% and 3.7% of patients, respectively. Basal 
HealthCoin ≥ PCure - EINMBNE, Private , where INMBMedicare is the incremental 
net monetary benefits (INMB) to Medicare of a cure of diabetes for a 65-years old, 
EINMBNE, Private is the average INMB to the private payer for a cure of diabetes 
across all non-elderly incident population with diabetes, and PCureis the market 
price for the cure. Using empirical estimates, we explore whether a developing 
such a HealthCoin would be feasible. CONCLUSIONS: We find, theoretically, that 
developing such a HealthCoin may be feasible for a cure of diabetes. Extension of 
this work would explore how such HealthCoins can be traded within the private 
sector and also in other disease areas.
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OBJECTIVES: Women with Gestational Diabetes Mellitus (GDM) have six times higher 
risk of developing Diabetes Mellitus (DM) type 2 compared to women who don’t have 
GDM. The purpose of this study was to evaluate the protective effects of breast-feeding 
on development of DM in women with GDM. METHODS: This was a cross sectional 
study where a secondary database analysis was done using National Health and 
Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010 and 2011-2012. 
Females 20 to 75 years with at least one live birth were included. Chi-square-test 
compared differences between categorical variables and t-test examined differences 
in the means for continuous variables. Unadjusted-odds-ratio was calculated using 
logistic regression to examine breastfeeding as an effect modifier in the association 
between GDM and DM. Model was adjusted for age, BMI, race/ethnicity, income, edu-
cation, age at DM and number of live births. Sample weights and the stratification 
and clustering of the design were incorporated to obtain proper estimates. RESULTS: 
The final analytic sample consisted of 6503 participants. Percentage of GDM women 
who breast-fed seemed higher than women without GDM (64.6 % vs. 44.9%). Among 
women who breastfed, the odds ratio for developing DM in women with GDM was 
3.3 (95% CI 2.3, 4.9) compared to those without GDM while, in women who never 
breastfed, the odds ratio was 3.9 (95% CI 2.3, 6.6). After adjusting for age, BMI, race/
ethnicity, education and number of live births, OR for the association between DM and 
GDM was 2.2 (1.4, 3.4) in women who breastfed and 2.8 (1.6, 4.9) in women who didn’t 
breast feed. CONCLUSIONS: This analysis found that there’s potential benefit of BF 
in the prevention of DM among women who had GDM. This result adds to the already 
known important benefits of BF and more women should be encouraged to BF.
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OBJECTIVES: Most endocrine disorders are chronic diseases that need life-long 
care. Some of the most common endocrine diseases include diabetes mellitus, 
hypothyroidism and metabolic syndrome. Although most of the patients suffering 
of these diseases are followed by their primary care physician, definite diagno-
sis, initiation/change of treatment and chronic care of the disease is ensured by 
the endocrinologist. The objective of this study was to evaluate an endocrinolo-
gist electronic medical record (EMR) database to assess its feasibility for use in 
observational studies. METHODS: We analyzed de-identified patient data from 
Longitudinal Patient Database (LPD) Endocrinologist panel, including endocrinolo-
gists from 2013-2014. Comprehensiveness and completeness of each variable by 
visit was evaluated. Characteristics of physicians and patient population were 
compared to published sources. RESULTS: There were 77 243 visits by 34 492 active 
patients (= 1 visit per year) to 40 physicians. Completeness of each variable by visit 
ranked from 100% to 27% for sex, age and laboratory results. Most of these patients 
(73%) were female. Analysis of diagnosis associated to visits revealed that 32 % 
were related to diabetes, while 32% and 9% were related to thyroid disorders and 
obesity respectively. Among diabetic patients, 50% were female, and 74% had type 
2 diabetes. An average BMI of 30 and HbA1C of 7.4% was recorded. Among treated 
patients 38% received sulfonylureas and 59 % biguanides. A third of the patients 
(34%) received one, another third (33%) received two, and another third (33%) three 
or more anti-diabetic treatments (including insulin). Insulin was prescribed, alone 
or in combination, in 36% of cases. The comparison of these data with literature 
is presented. CONCLUSIONS: This panel is still new and needs further validation 
studies. Good agreement with published data suggests this may be a valuable tool 
to support observational studies.
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OBJECTIVES: Sulfonylureas (SU) are a widely-prescribed class of oral medications 
used to treat type 2 diabetes mellitus and are known to cause hypoglycemic events 
(HE) and weight gain. In this survey, we aimed to identify reasons reported by physi-
cians for discontinuing (DC) or down-titrating (DT) SU therapy. METHODS: Primary 
care physicians (PCPs) and specialists (endocrinologists and diabetologists) were 
recruited from the AllGlobal panel, an actively managed, double opt-in panel of 
physicians. Participants were asked to rate their level of concern regarding potential 
reasons for DC or DT on a 7-point Likert scale (1= not at all concerned, 7= extremely 
concerned). In addition, physicians reviewed one chart each from a typical SU 
patient with DC or DT in the previous 6 months and 2 current SU patients without 
DC or DT in the previous 6 months to collect patient characteristics and medical 
history. RESULTS: 776 PCPs and 250 specialists participated, of whom 76% were 
male and 93% were aged 35 to 64. Physicians reported highest concern about HE 
